GILD News and Press, Gilead Sciences Inc. From 04/23/24

2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...

2024-04-23 09:00:03 ET Summary GILD stock has given up most of its late-2022 gains due to sector-wide underperformance and disappointing data from the EVOKE-01 Phase 3 trial. Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25. Hence, and considering my last art...

2024-04-22 15:04:08 ET Summary The FDA approved Mirum Pharmaceuticals, Inc.'s Limvarli for treatment of cholestatic pruritus in patients with Progressive Familial Intrahepatic Cholestasis; Potential for further label expansion in younger patients possible due to positive MARCH study. ...

2024-04-22 14:20:23 ET Summary Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design.  A Phase 2a clinical update is due in 2Q'24. The company's shares closed at $0.733, with a valuation of approximately $72.53.  Positive data ...

2024-04-22 13:04:43 ET Summary Heightened geopolitical risk has caught investors flat-footed over the past week. A historical analogy is presented of the Cuban Missile Crisis, a time of even greater geopolitical risk. In the short term, selling pressure in the market is likely...

2024-04-22 12:03:00 ET Summary The stock of Gilead Sciences, Inc. has underperformed the market substantially over the past decade, but there are some signs developing of a potential bottom. The stock offers a high dividend yield of 4.61% and is trading at a low valuation compared...

2024-04-21 08:00:00 ET As the market gears up for another eventful earnings week, investors are eagerly anticipating reports from a wide array of companies across various sectors. Big names like Tesla ( NASDAQ: TSLA ), Microsoft ( NASDAQ: MSFT ), Alphabet ( NASDAQ: GOOG ...

2024-04-20 12:03:00 ET Summary abrdn Healthcare Opportunities Fund (THQ) offers a high dividend yield of 11.3% and exposure to diverse subsectors of the healthcare industry. The fund outperforms its peers, abrdn World Healthcare Fund (THW) and BlackRock's Health Sciences Trust (BM...

2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...

2024-04-19 06:13:03 ET More on Bristol-Myers Squibb, Gilead, etc. Johnson & Johnson: Buy This Bargain Before It's Gone Bristol-Myers Squibb: Market Pessimism Won't Last Forever Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript FDA approves Alvo...